provocative testing raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Das RC, Heath EC (1980). "Dolichyldiphosphoryloligosaccharide--protein oligosaccharyltransferase; solubilization, purification, and properties". Proc. Natl. Acad. Sci. U.S.A. 77 (7): 3811–5. Bibcode:1980PNAS...77.3811D. doi:10.1073/pnas.77.7.3811. PMC 349716. PMID 6933437.
The black desert cobra (Walterinnesia aegyptia) is a highly venomous snake species found in the Middle East. The subcutaneous LD50 for the venom of this species is 0.40 mg/kg. For comparison, the Indian cobra's (naja naja) subcutaneous LD50 is 0.80 mg/kg, while the Cape cobra's (naja nivea) subcutaneous LD50 is 0.72 mg/kg. This makes the black desert cobra a more venomous species than both. The venom is strongly neurotoxic and also has mild hemotoxic factors. Envenomation usually causes some combination of local pain, swelling, fever, general weakness, headache, & vomiting. This is not a typically aggressive snake, but it will strike and hiss loudly when provoked. It can strike at a distance of two-thirds of its body length. It does not usually spread a hood nor hold up its body up off the ground like true cobras do. Envenomation by this species should be considered a serious medical emergency. Human fatalities due to envenomation by this species have been reported.
=== Crime and punishment === In Green Lantern (vol. 3) #54 (August 1994), Major Force kills Alexandra DeWitt, girlfriend of Green Lantern Kyle Rayner, and stuffs her remains in a refrigerator for Kyle to find. Kyle tortures Major Force after their fight, but is stopped by the Los Angeles Police Department. In an issue of Guy Gardner: Warrior, Major Force seemingly kills Guy Gardner's mother in the same manner as Alex. Gardner, who has awakened his Vuldarian abilities, kills Major Force with a shifted weapon's edge. The Quorum, who previously hired Major Force to harass Rayner and Gardner, resurrect him and enhance him with Vuldarian DNA. Major Force kills Arisia Rrab, a Green Lantern and friend of Gardner, as a declaration of war against him.
Sources: en.wikipedia.org
Pakistan's economy ranks 27th globally by purchasing power parity (PPP) and 42nd by nominal GDP. Historically, Pakistan was part of the wealthiest region in the first millennium CE, but lost ground to regions like China and Western Europe by the 18th century. Pakistan is a developing country, and part of the Next Eleven, poised to become one of the world's largest economies in the 21st century, alongside the BRIC countries. The semi-industrialised economy is heavily dependent on agriculture, and industrial growth in Pakistan benefits significantly from agricultural expansion. Pakistan's economy has shifted from agriculture to trade and services, with agriculture contributing about one-fifth of GDP and manufacturing one-sixth, while trade and services form the largest share. In 2023, Pakistan was the 66th-largest export economy, with a trade deficit of US$21.3 billion.
The thermosynthesis hypothesis considers chemiosmosis more basal than fermentation: the ATP synthase enzyme, which sustains chemiosmosis, is the currently extant enzyme most closely related to the first metabolic process. The thermosynthesis hypothesis does not even invoke a pathway: ATP synthase's binding change mechanism resembles a physical adsorption process that yields free energy. The result would be convection which would bring a continual supply of reactants to the protoenzyme. The described first protein may be simple in the sense that it requires only a short sequence of conserved amino acid residues, a sequent sufficient for the appropriate catalytic cleft.
The Ilyushin Il-86 (Russian: Илью́шин Ил-86; NATO reporting name: Camber) is a retired short- to medium-range wide-body jet airliner that served as the USSR's first wide-bodied aircraft. Designed and tested by the Ilyushin design bureau in the 1970s, it was certified by the Soviet aircraft industry, manufactured and marketed by the USSR. Developed during the rule of Leonid Brezhnev, the Il-86 was marked by the economic and technological stagnation of the era: it used engines more typical of the late 1960s, spent a decade in development, and failed to enter service in time for the 1980 Summer Olympics in Moscow, as was originally intended. The type was used by Aeroflot and successor post-Soviet airlines; only three of the total 106 constructed were exported. At the beginning of 2012, only four Il-86s remained in service, all with the Russian Air Force. By the end of 2020 the number in active service was reduced to three.
== Release == Ninnu Kori was released on 7 July 2017. Later, a Hyderabad-Mumbai based production company, Aditya Movies bought the Hindi dubbing rights of the film. It is dubbed into Hindi as Aaj Ka Khiladi in 2020 which is to have a direct premiere on TV channel. Sony Networks bought the satellite rights of the Hindi dubbed version.
Sources: en.wikipedia.org
Thorium and protactinium, but not uranium compounds, are poorly soluble in aqueous solutions and precipitate into sediments; the precipitation rate is faster for thorium than for protactinium. The concentration analysis for both protactinium-231 (half-life 32,760 years) and 230Th (half-life 75,380 years) improves measurement accuracy compared to when only one isotope is measured; this double-isotope method is also weakly sensitive to inhomogeneities in the spatial distribution of the isotopes and to variations in their precipitation rate.
=== Therapeutic insights === The distinct structure of RAGE makes it a potential target for therapeutic intervention, particularly in conditions involving chronic inflammation. Inhibitors that prevent ligand binding to the V domain have been studied to reduce downstream inflammatory signaling. Targeting the cytoplasmic domain to disrupt intracellular signal transduction is another approach being explored. Additionally, increasing the levels of sRAGE could serve as an effective strategy to neutralize pro-inflammatory ligands and limit their interaction with mRAGE, offering potential benefits in treating inflammatory conditions.
After the rule of the Jagiellonian dynasty ended in 1572, Henry of Valois (later King Henry III of France) was the winner of the first "free election" by the Polish nobility, held in 1573. He had to agree to the restrictive pacta conventa obligations and fled Poland in 1574 when news arrived of the vacancy of the French throne, to which he was the heir presumptive. From the start, the royal elections increased foreign influence in the Commonwealth as foreign powers sought to manipulate the Polish nobility to place candidates amicable to their interests. The reign of Stephen Báthory of Hungary followed (r. 1576–1586). He was militarily and domestically assertive and is revered in Polish historical tradition as a rare case of a successful elective king. The establishment of the legal Crown Tribunal in 1578 meant a transfer of many appellate cases from the royal to noble jurisdiction.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.